GLP-1 Coverage Is Expanding — But Clinical Support Isn't Keeping Up
GLP-1 medications have officially crossed from niche pharmaceutical products into mainstream employee benefits. According to the Kaiser Family Foundation's Employer Health Benefits Survey, approximately 19% of large employers now cover GLP-1 drugs used primarily for weight loss. Among employers with 5,000 or more workers, that figure jumps to 43%. For HR leaders, this signals a significant shift in how organizations are approaching metabolic health and weight management as part of their total benefits strategy.
But coverage alone doesn't tell the full story. As GLP-1 medications and hormone therapies become a standard line item in employer health plans, a critical gap is emerging — one that most HR teams haven't yet found a reliable way to measure. That gap is clinical follow-up care, and new research suggests it may be costing employers far more than they realize.
What the Research Reveals About Follow-Up Care Failures
Maven's Beyond the Script report surveyed 1,538 women and 520 healthcare providers across the United States to understand what happens after a GLP-1 or hormone therapy prescription is written. The findings paint a striking picture of a system that writes prescriptions but doesn't reliably support the patients who fill them.
Thirty-seven percent of women who used medications for weight management, metabolism, or hormonal health said that follow-up care felt limited, inconsistent, or nonexistent. That's more than one in three patients navigating a complex, ongoing medication regimen largely on their own.
The problems aren't limited to the patient side of the equation. Providers describe a parallel challenge. Forty-one percent of surveyed healthcare providers said they don't have enough visit time to adequately support patients after prescribing GLP-1 medications. Perhaps more concerning, nearly half reported uncertainty about when GLP-1s are clinically appropriate in the first place. When prescribers themselves feel unsupported by the systems around them, the downstream effects on patient outcomes — and employer costs — are significant.
Why GLP-1s and Hormone Therapies Demand More Than a Prescription
A fundamental misunderstanding embedded in many current benefits designs is the idea that covering the medication is the same as covering the treatment. GLP-1s and hormone therapies are not one-and-done interventions. They are ongoing, dynamic treatments that interact with multiple dimensions of a patient's health profile.
These medications intersect with reproductive history, hormonal health, mental health, and metabolic function in ways that evolve over time. A patient's needs at month one of a GLP-1 regimen may look entirely different from their needs at month six. Without consistent clinical oversight, patients may experience side effects that go unaddressed, dosing that isn't optimized, or co-occurring hormonal issues that are never identified — all of which undermine the value of the benefit employers are paying for.
This complexity means that coordinated, longitudinal care isn't a nice-to-have. It's a clinical necessity. And right now, for a large share of the workforce using these medications, that coordination simply isn't there.
The Hidden Cost Accumulating in Claims, Productivity, and Retention
For HR and benefits leaders, the downstream implications of this care gap are significant and multifaceted. When prescription coverage isn't paired with clinical follow-through, the cost doesn't disappear — it accumulates in less visible places.
- Claims costs: Patients who don't receive adequate follow-up care are more likely to experience complications, discontinue medications prematurely, or cycle through multiple prescriptions before finding an effective approach. Each of these scenarios generates additional claims activity that erodes the ROI employers hoped to achieve by covering GLP-1s in the first place.
- Productivity losses: Undertreated metabolic and hormonal conditions are strongly associated with fatigue, cognitive difficulty, mood disruption, and absenteeism. Employees who are taking medications but not experiencing clinical improvement represent a hidden productivity cost that rarely surfaces in standard HR reporting.
- Retention risks: Benefits that feel incomplete or unsupportive send a message to employees — particularly women, who disproportionately use hormone therapies and are increasingly using GLP-1s. If employees feel that their health needs aren't being meaningfully addressed by their benefits package, that perception influences engagement, loyalty, and ultimately retention.
The challenge for most HR teams is that these costs are difficult to attribute directly to a follow-up care gap. They show up diffusely across claims data, manager feedback, and exit interviews rather than appearing as a line item. That invisibility is part of what makes this problem so persistent.
What Employers Can Do to Close the Gap
Recognizing the problem is the essential first step. The next is building benefits infrastructure that matches the clinical reality of what GLP-1 and hormone therapy patients actually need. Several approaches are gaining traction among forward-thinking employers.
Virtual care platforms that specialize in women's health and metabolic care are increasingly positioned to provide the kind of coordinated, ongoing support that in-person primary care often can't deliver within standard visit constraints. These platforms can wrap around an existing prescription benefit, ensuring that patients have access to clinical guidance, nutritional support, mental health resources, and medication management across the full arc of their treatment — not just at the moment a prescription is written.
Employers are also beginning to ask harder questions of their pharmacy benefit managers and health plan partners about what clinical support frameworks exist for GLP-1 patients. Does the plan include nurse navigation? Is there a protocol for checking in with patients at 30, 60, and 90 days? Are hormonal health considerations integrated into the medication management process? These questions are increasingly relevant to evaluating whether a GLP-1 benefit is delivering real value.
The Bottom Line for Benefits Strategy
GLP-1 medications and hormone therapies represent a genuine opportunity for employers to support workforce health in meaningful, measurable ways. Coverage is the foundation — but coverage without clinical follow-through is an incomplete investment. As adoption grows and costs rise, employers who pair prescription access with robust ongoing care infrastructure will be better positioned to see real returns: healthier employees, lower long-term claims, and a benefits package that employees actually trust.
The follow-up problem is solvable. The first step is acknowledging that it exists.